Over a decade since gene therapy development came to a near standstill with the death of a clinical trial participant, the field is overcoming issues of immunogenicity, carcinogenicity, manufacturing and small patient populations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maguire, A. M. et al. N. Engl. J. Med. 358, 2240–2248 (2008).
Cavazzana-Calvo, M. et al. Nature 467, 318–322 (2010).
Boztug, K. et al. N. Engl. J. Med. 363, 1918–1927 (2010).
Porter, D. L. et al. N. Engl. J. Med. 365, 725–733 (2011).
Aiuti, A. et al. N. Engl. J. Med. 360, 447–458 (2009).
Gaspar, H. B. et al. Sci. Transl. Med. 3, 97ra80 (2011).
Gaspar, H. B. et al. Sci. Transl. Med. 3, 97ra79 (2011).
Cavazzana-Calvo, M. et al. Science 288, 669–672 (2000).
Kay, M. A. Nature Rev. Genet. 12, 316–328 (2011).
Rights and permissions
About this article
Cite this article
Mullard, A. Gene therapies advance towards finish line. Nat Rev Drug Discov 10, 719–720 (2011). https://doi.org/10.1038/nrd3572
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3572
This article is cited by
-
Rare Diseases: Drug Discovery and Informatics Resource
Interdisciplinary Sciences: Computational Life Sciences (2018)
-
Glybera and the future of gene therapy in the European Union
Nature Reviews Drug Discovery (2012)
